Skip to main content

Table 2 Changes in the WOMAC score during the treatment in PP populationa

From: Treatment of knee osteoarthritis with a new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin: a multicenter, randomized, single-blind, non-inferiority clinical trial

WOMAC

GS/ CS

(N = 209)

RP

(N = 223)

Difference between the treatments

CI (95%)

Absolute change in score of WOMAC “pain” subscale, mm, mean (se)

Week 6

- 18.2 (1.7)

- 20.2 (1.72)

1.98 (2)

(− 1.95; 5.9)

Week 12

- 23.3 (1.7)

- 24.7 (1.7)

1.3 (2)

(− 2.6; 5.3)

Week 24

- 32.8 (1.8)

−33.3 (1.7)

0.54 (2)

(− 3.5; 4.5)

Absolute change in score of WOMAC “stiffness” subscale, mm, mean (se)

Week 6

- 15.4 (2)

- 17 (2)

1.6 (2.3)

(− 3; 6.1)

Week 12

- 19.1 (2)

- 22.5 (2)

3.4 (2.3)

(− 1.1; 8)

Week 24

- 28.6 (2)

- 30.1 (2)

1.4 (2.4)

(− 3.2; 6.1)

Absolute change in score of WOMAC “function” subscale, mm, mean (se)

Week 6

- 14.2 (1.7)

- 15.1 (1.7)

0.9 (2)

(− 2.94; 4.78)

Week 12

- 19.6 (1.7)

- 21.4 (1.7)

1.8 (2)

(−  2.1; 5.7)

Week 24

- 28.9 (1.8)

- 29.5 (1.7)

0.6 (2)

(− 3.3; 4.5)

Absolute change in WOMAC total score, mm, mean (se)

Week 6

- 48.1 (5.1)

- 52.83 (5)

4.8 (5.8)

(− 6.6; 16.1)

Week 12

- 62.3 (5.1)

- 69.1 (5)

6.9 (5.8)

(− 4.6; 18.3)

Week 24

- 90.6 (5.1)

- 93.4 (5.1)

2.9 (5.9)

(−8.7; 14.4)

  1. aEstimates of the mixed model for repeated measures adjusted per baseline score and site. CI (95%) two-sided confidence interval for change mean, with confidence coefficient of 95%, GS/CS glucosamine sulfate/ chondroitin sulfate, PP per protocol, RP Reference Product, se standard estimate, WOMAC Western Ontario and McMaster Universities questionnaire (score normalized at the scale from 0 to 100 mm)